Compounders Research Compare

Immunome, Inc.(IMNM)

Biotechnology · Bothell, WA

$20.60-0.57 (-2.71%)

Delayed quote: Oct 6, 2026, 11:35 AM EDT

About Immunome, Inc.

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Bothell, WA

247 employees

www.immunome.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Clay Siegall

View full financials

EV/EBIT Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBIT ratio is N/A as of 2026-10-06T15:37:07.445Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:37:07.445Z.

Quote observation: 2026-10-06T15:35:06.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,968,869,962
Total debt · period ending 2026-06-30: 4,588,000
Cash · period ending 2026-06-30: 217,706,000
TTM operating income · period ending 2026-06-30: -270,465,000

FMP input reference: 243952859d49b374df7eb324c8bbcd7e4caeb894f26e22f2834818a88b726353

EV/EBITDA|EV/Sales|Operating Income|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

IMNM EV/EBIT Ratio Metrics

EV/EBIT RATIO

N/A

IMNM Competitors' EV/EBIT Ratio

Immunome, Inc.

Current

Market Cap

$1.97B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AxoGen, Inc.

Market Cap

$1.96B

EV/EBIT Ratio

N/A

TTM Avg

408.25x

3Y Avg

408.25x

5Y Avg

408.25x

Establishment Labs Holdings Inc.

Market Cap

$1.95B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Inspire Medical Systems, Inc.

Market Cap

$2.00B

EV/EBIT Ratio

35.17x

TTM Avg

44.12x

3Y Avg

112.76x

5Y Avg

112.76x

Aurinia Pharmaceuticals Inc.

Market Cap

$2.03B

EV/EBIT Ratio

12.67x

TTM Avg

22.52x

3Y Avg

26.44x

5Y Avg

26.44x

Progyny, Inc.

Market Cap

$2.03B

EV/EBIT Ratio

17.01x

TTM Avg

21.63x

3Y Avg

33.37x

5Y Avg

79.37x

Mineralys Therapeutics, Inc.

Market Cap

$2.03B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Agios Pharmaceuticals, Inc.

Market Cap

$1.90B

EV/EBIT Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BioLife Solutions, Inc.

Market Cap

$1.89B

EV/EBIT Ratio

251.96x

TTM Avg

240.22x

3Y Avg

240.22x

5Y Avg

240.22x

Novavax, Inc.

Market Cap

$1.87B

EV/EBIT Ratio

N/A

TTM Avg

3.63x

3Y Avg

3.63x

5Y Avg

3.63x

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
Immunome, Inc. (IMNM)	$1.97B	N/A	N/A	N/A	N/A
AxoGen, Inc. (AXGN)vs ›	$1.96B	N/A	408.25x	408.25x	408.25x
Establishment Labs Holdings Inc. (ESTA)vs ›	$1.95B	N/A	N/A	N/A	N/A
Inspire Medical Systems, Inc. (INSP)vs ›	$2.00B	35.17x	44.12x	112.76x	112.76x
Aurinia Pharmaceuticals Inc. (AUPH)vs ›	$2.03B	12.67x	22.52x	26.44x	26.44x
Progyny, Inc. (PGNY)vs ›	$2.03B	17.01x	21.63x	33.37x	79.37x
Mineralys Therapeutics, Inc. (MLYS)vs ›	$2.03B	N/A	N/A	N/A	N/A
Agios Pharmaceuticals, Inc. (AGIO)vs ›	$1.90B	N/A	N/A	N/A	N/A
BioLife Solutions, Inc. (BLFS)vs ›	$1.89B	251.96x	240.22x	240.22x	240.22x
Novavax, Inc. (NVAX)vs ›	$1.87B	N/A	3.63x	3.63x	3.63x

EV/EBIT Ratio Formula & Definition

EV/EBIT = Enterprise Value / EBIT (TTM)

Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA EV/Sales Operating Income All Metrics